Literature DB >> 18060370

Recent discoveries in the genetics of melanoma and their therapeutic implications.

Amélie Marquette1, Martine Bagot, Armand Bensussan, Nicolas Dumaz.   

Abstract

The incidence of cutaneous malignant melanoma, tumors arising from melanocytes, has increased markedly over the past few years in many countries. Although early melanoma is curable through surgical excision, the prognosis of advanced melanoma is very poor, this tumor being resistant to current therapies. Thus there is a need for new therapies to improve the treatment of advanced melanoma. This review provides an overview of recent discoveries in the genetics of melanoma which could offer new therapeutic opportunities.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18060370      PMCID： PMC2682195          DOI： 10.1007/s00005-007-0043-5

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN： 0004-069X            Impact factor:   4.291


  74 in total

Review 1.  The RAF proteins take centre stage.

Authors:  Claudia Wellbrock; Maria Karasarides; Richard Marais
Journal:  Nat Rev Mol Cell Biol       Date:  2004-11       Impact factor: 94.444

2.  The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase.

Authors:  J E Damen; L Liu; P Rosten; R K Humphries; A B Jefferson; P W Majerus; G Krystal
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

Review 3.  Cutaneous melanoma.

Authors:  John F Thompson; Richard A Scolyer; Richard F Kefford
Journal:  Lancet       Date:  2005 Feb 19-25       Impact factor: 79.321

4.  Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.

Authors:  Derek L Dai; Magdalena Martinka; Gang Li
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

5.  Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.

Authors:  P Guldberg; P thor Straten; A Birck; V Ahrenkiel; A F Kirkin; J Zeuthen
Journal:  Cancer Res       Date:  1997-09-01       Impact factor: 12.701

Review 6.  Normal and oncogenic forms of the receptor tyrosine kinase kit.

Authors:  Johan Lennartsson; Tanya Jelacic; Diana Linnekin; R Shivakrupa
Journal:  Stem Cells       Date:  2005       Impact factor: 6.277

7.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

Authors:  John Rinehart; Alex A Adjei; Patricia M Lorusso; David Waterhouse; J Randolph Hecht; Ronald B Natale; Oday Hamid; Mary Varterasian; Peggy Asbury; Eric P Kaldjian; Stephen Gulyas; David Y Mitchell; Roman Herrera; Judith S Sebolt-Leopold; Mark B Meyer
Journal:  J Clin Oncol       Date:  2004-10-13       Impact factor: 44.544

8.  c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype.

Authors:  T Otsuka; H Takayama; R Sharp; G Celli; W J LaRochelle; D P Bottaro; N Ellmore; W Vieira; J W Owens; M Anver; G Merlino
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

9.  Expression of c-kit receptor in normal and transformed human nonlymphoid tissues.

Authors:  P G Natali; M R Nicotra; I Sures; E Santoro; A Bigotti; A Ullrich
Journal:  Cancer Res       Date:  1992-11-15       Impact factor: 12.701

10.  Loss of c-kit expression in cultured melanoma cells.

Authors:  N Lassam; S Bickford
Journal:  Oncogene       Date:  1992-01       Impact factor: 9.867
View more
  8 in total

Review 1.  Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Authors:  Gajanan S Inamdar; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Biochem Pharmacol       Date:  2010-05-09       Impact factor: 5.858

Review 2.  Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells.

Authors:  Yunyi Kong; Suresh M Kumar; Xiaowei Xu
Journal:  Arch Pathol Lab Med       Date:  2010-12       Impact factor: 5.534

3.  Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma.

Authors:  Nicolas Dumaz
Journal:  Small GTPases       Date:  2011-09-01

4.  Cryptotanshinone has diverse effects on cell cycle events in melanoma cell lines with different metastatic capacity.

Authors:  Lei Chen; Shi-zhong Zheng; Zhi-guang Sun; Ai-yun Wang; Chen-hu Huang; Neville A Punchard; Shi-le Huang; Xiang Gao; Yin Lu
Journal:  Cancer Chemother Pharmacol       Date:  2010-09-04       Impact factor: 3.333

5.  CB-RAF600E-1 exerts efficacy in vemurafenib-resistant and non-resistant-melanoma cells via dual inhibition of RAS/RAF/MEK/ERK and PI3K/Akt signaling pathways.

Authors:  Mesfer Al Shahrani; Prasanna Rajagopalan; Mohammad Abohassan; Mohammad Alshahrani; Yasser Alraey
Journal:  Saudi J Biol Sci       Date:  2022-04-23       Impact factor: 4.052

6.  Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications.

Authors:  Peng Hou; Dingxie Liu; Meiju Ji; Zhi Liu; James M Engles; Richard L Wahl; Mingzhao Xing
Journal:  PLoS One       Date:  2009-07-10       Impact factor: 3.240

Review 7.  Current and future trials of targeted therapies in cutaneous melanoma.

Authors:  Matthew S Evans; Subbarao V Madhunapantula; Gavin P Robertson; Joseph J Drabick
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

8.  Functional effects of GRM1 suppression in human melanoma cells.

Authors:  Janet Wangari-Talbot; Brian A Wall; James S Goydos; Suzie Chen
Journal:  Mol Cancer Res       Date:  2012-07-13       Impact factor: 5.852
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.